Elsmarieke van de Giessen - Academia.edu (original) (raw)
Papers by Elsmarieke van de Giessen
Neuroscience Applied, Dec 31, 2022
Alzheimer's & Dementia, Nov 30, 2023
Schizophrenia Research, Nov 30, 2023
Journal of Cerebral Blood Flow and Metabolism, May 26, 2023
Aging-related cognitive decline can be accelerated by a combination of genetic factors, cardiovas... more Aging-related cognitive decline can be accelerated by a combination of genetic factors, cardiovascular and cerebrovascular dysfunction, and amyloid-β burden. Whereas cerebral blood flow (CBF) has been studied as a potential early biomarker of cognitive decline, its normal variability in healthy elderly is less known. In this study, we investigated the contribution of genetic, vascular, and amyloid-β components of CBF in a cognitively unimpaired (CU) population of monozygotic older twins. We included 134 participants who underwent arterial spin labeling (ASL) MRI and [18F]flutemetamol amyloid-PET imaging at baseline and after a four-year follow-up. Generalized estimating equations were used to investigate the associations of amyloid burden and white matter hyperintensities with CBF. We showed that, in CU individuals, CBF: 1) has a genetic component, as within-pair similarities in CBF values were moderate and significant (ICC > 0.40); 2) is negatively associated with cerebrovascular damage; and 3) is positively associated with the interaction between cardiovascular risk scores and early amyloid-β burden, which may reflect a vascular compensatory response of CBF to early amyloid-β accumulation. These findings encourage future studies to account for multiple interactions with CBF in disease trajectory analyses.
Springer eBooks, 2014
The neurotransmitter dopamine plays a role in many different functions of the human brain, rangin... more The neurotransmitter dopamine plays a role in many different functions of the human brain, ranging from psychomotor planning to cognition. This short review addresses which parts of the dopamine system can be imaged quantitatively in the living human brain using positron-emission tomography (PET) or single-photon emission computed tomography (SPECT).
Springer eBooks, Nov 11, 2021
Neurology
Background and Objectives Recently, the US Food and Drug Administration approved the tau-binding ... more Background and Objectives Recently, the US Food and Drug Administration approved the tau-binding radiotracer [18F]flortaucipir and an accompanying visual read method to support the diagnostic process in cognitively impaired patients assessed for Alzheimer disease (AD). Studies evaluating this visual read method are limited. In this study, we evaluated the performance of the visual read method in participants along the AD continuum and dementia with Lewy bodies (DLB) by determining its reliability, accordance with semiquantitative analyses, and associations with clinically relevant variables. Methods We included participants who underwent tau-PET at Amsterdam University Medical Center. A subset underwent follow-up tau-PET. Two trained nuclear medicine physicians visually assessed all scans. Inter-reader agreement was calculated using Cohen κ. To examine the concordance of visual read tau positivity with semiquantification, we defined standardized uptake value ratio (SUVr) positivity ...
ISMRM Annual Meeting
The current study assesses neuromelanin sensitive MRI (NM-MRI) as a potential biomarker for treat... more The current study assesses neuromelanin sensitive MRI (NM-MRI) as a potential biomarker for treatment resistance (TR) in first episode schizophrenia patients. NM-MRI is a novel MRI sequence, which indirectly measures dopamine synthesis. Research using positron emission tomography (PET) imaging suggest that TR patients show lower dopamine synthesis than responders. We acquired NM-MRI in 61 first episodes schizophrenia patients. Treatment response was determined during 6 months follow-up. TR patients showed significantly lower NM-MRI signal compared to responders. These findings are in line with previous PET studies and demonstrate the potential of NM-MRI as alternative and more accessible biomarker for TR.
Obesity, Aug 1, 2012
Different types of high‐fat (HF) diets are used to study diet‐induced obesity (DIO) in rodents an... more Different types of high‐fat (HF) diets are used to study diet‐induced obesity (DIO) in rodents and this has led to different phenotypes. This study assesses whether different HF diets differentially affect striatal dopamine D2/3 receptor (DRD2/3) availability, as decreased striatal DRD2/3 availability has been implicated in obesity in relation to reward deficiency for food. Thirty rats were randomized to either a free‐choice HF diet (HF‐choice), a premixed HF diet (HF‐no‐choice), or a standard chow diet for 28 days. Striatal DRD2/3 was measured using 123I‐IBZM storage phosphor imaging at day 29. DRD2/3 availability was significantly decreased in the dorsal striatum in the HF‐choice rats compared to chow rats, but not in HF‐no‐choice rats. Additionally, caloric intake of the HF‐choice rats was significantly higher than that of HF‐no‐choice rats and serum leptin and percentage abdominal fat store weight of total body weight were significantly higher in the HF‐choice rats compared to chow rats. These preliminary results suggest that the choice element in HF diets, which is possibly related to the motivational aspects of eating, leads to overconsumption and to a distinct state of obesity. These results are relevant for future studies on DIO when considering choice of diet type.
Therapeutic Advances in Psychopharmacology, 2019
Treatment resistance (TR) in psychosis is a major clinical problem. A biomarker predicting TR aga... more Treatment resistance (TR) in psychosis is a major clinical problem. A biomarker predicting TR against conventional antipsychotic drugs would be relevant, potentially reducing unnecessary delay to adequate treatment with clozapine. Dopa decarboxylase (DDC) activity in the striatum, measured with positron emission tomography, is elevated in responders, but not in treatment-resistant patients. Plasma DDC activity could be a surrogate marker for DDC brain activity, and thus a potential biomarker that could be used in daily clinical practice. Therefore, we determined plasma DDC activity in 40 male patients with recent-onset psychosis, of whom the majority had started treatment, whereby 21 turned out to be treatment responders and 19 treatment resistant during follow up. We observed no significant group differences. Furthermore, symptom severity was not associated with plasma DCC activity. We did observe a trend level difference in the distribution of plasma DDC activity across categories of medication, with subsequent post hoc analysis showing lower DDC activity in risperidone-using patients. This may suggest that risperidone could influence plasma DDC activity. Based on these results, plasma DDC activity does not appear to be a promising biomarker for TR in recent-onset psychosis patients who are already receiving antipsychotic treatment.
Neuroscience applied, 2023
Oxford University Press eBooks, Feb 1, 2016
Neurobiological aspects of obesity: dopamiNe, serotoNiN, aNd imagiNg academiscH proefscHrift ter ... more Neurobiological aspects of obesity: dopamiNe, serotoNiN, aNd imagiNg academiscH proefscHrift ter verkrijging van de graad van doctor aan de universiteit van amsterdam op gezag van de rector magnificus prof. dr. d.c. van den boom ten overstaan van een door het college voor promoties ingestelde commissie, in het openbaar te verdedigen in de agnietenkapel op woensdag 14 november 2012, te 14:00 uur door elisabeth maaike van de giessen geboren te papendrecht promotiecommissie promotores: prof. dr. J. booij prof. dr. W. van den brink co-promotores: prof. dr. f. baas dr. s.e. la fleur overige leden: prof. dr. e. derks prof. dr. b.l.f. van eck-smit prof. dr. a. Jansen prof. dr. t.J. de Vries dr. l. reneman faculteit der geneeskunde Voor Mark geNeral iNtroductioN aNd outliNe of tHesis geNeral iNtroductioN obesity obesity is a condition with an excess proportion of body fat. the most commonly used definition for obesity, as defined by the World Health organization (WHo), is a body mass index (bmi) of > 30 kg/m 2 , whereas a bmi between 25-30 kg/m 2 is defined as overweight, a bmi between 18.5-25 kg/m 2 as normal-weight, and a bmi below 18.5 kg/m 2 as underweight. in addition, the category morbid obesity has been used for people with a bmi > 40 kg/m 2. the growing obesity epidemic is a well-recognized health problem. in the united states, over 30% of the adult population is obese (1). in the Netherlands, this number has doubled from 5.3% in 1981 to 11.4% in 2011 (staline.cbs.nl). the obesity epidemic is not restricted to the Western world (2), but is also increasing in urban areas of some low-and middle-income countries (fig. 1). obesity leads to higher mortality and is a major risk factor for diabetes mellitus, cardiovascular diseases, cancers, musculoskeletal disorders, major depression and also alzheimer's disease (3;4) the cause of obesity is an energy imbalance, i.e. too much energy intake relative to energy expenditure, leading to accumulation of fat mass in the body. the rise of the availability of palatable food, usually high-caloric food rich in sugars and fat, goes hand in hand with the rise in obesity (5;6) and is considered one of the major causes. still, the question remains why some people become obese and some do not in this high-caloric environment. this is a complex problem involving amongst others genetic factors and gene-environment interactions that influence metabolic and psychological mechanisms for regulation of food intake. Elsmarieke van de Giessen Silja McIlwrick dick Veltman Wim van den Brink Jan Booij in preparation.
European Neuropsychopharmacology, Mar 1, 2023
Springer eBooks, 2014
The brain is important in the regulation of eating behavior and satiety signaling. There is also ... more The brain is important in the regulation of eating behavior and satiety signaling. There is also evidence that many neurotransmitters are involved in food intake regulation and eating behavior; consequently dysregulated neurotransmitter systems may be involved in the pathophysiology of obesity. This chapter presents an overview of results of neurotransmitter imaging studies in obese humans and compares the findings to the available knowledge of animal research and to the literature on addiction and eating disorders.
Movement Disorders, Mar 15, 2022
European Neuropsychopharmacology, Apr 1, 2012
The novel triple monoamine inhibitor tesofensine blocks dopamine, serotonin and norepinephrine re... more The novel triple monoamine inhibitor tesofensine blocks dopamine, serotonin and norepinephrine reuptake and is a promising candidate for the treatment of obesity. Obesity is associated with lower striatal dopamine D2 receptor availability, which may be related to disturbed regulation of food intake. This study assesses the effects of chronic tesofensine treatment on food intake and body weight in association with changes in striatal dopamine D2/D3 receptor (D2/3R) availability of dietinduced obese (DIO) rats. Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+ restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg) +a treatment-free period of 28 days. Caloric intake and weight gain decreased significantly more in the tesofensine-treated rats compared to vehicle-treated rats, which confirms previous findings. After treatment discontinuation, caloric intake and body weight gain gradually increased again. Tesofensine-treated rats showed significantly lower D2/3R availability in nucleus accumbens and dorsal striatum than both vehicle-treated rats and vehicle-treated rats on restricted isocaloric diet. No correlations were observed between food intake or body weight and D2/3R availability. Thus, chronic tesofensine treatment leads to decreased food intake and weight gain. However, this appears not to be directly related to the decreased striatal D2/3R availability, which is mainly a pharmacological effect.
Neuroscience Applied, Dec 31, 2022
Alzheimer's & Dementia, Nov 30, 2023
Schizophrenia Research, Nov 30, 2023
Journal of Cerebral Blood Flow and Metabolism, May 26, 2023
Aging-related cognitive decline can be accelerated by a combination of genetic factors, cardiovas... more Aging-related cognitive decline can be accelerated by a combination of genetic factors, cardiovascular and cerebrovascular dysfunction, and amyloid-β burden. Whereas cerebral blood flow (CBF) has been studied as a potential early biomarker of cognitive decline, its normal variability in healthy elderly is less known. In this study, we investigated the contribution of genetic, vascular, and amyloid-β components of CBF in a cognitively unimpaired (CU) population of monozygotic older twins. We included 134 participants who underwent arterial spin labeling (ASL) MRI and [18F]flutemetamol amyloid-PET imaging at baseline and after a four-year follow-up. Generalized estimating equations were used to investigate the associations of amyloid burden and white matter hyperintensities with CBF. We showed that, in CU individuals, CBF: 1) has a genetic component, as within-pair similarities in CBF values were moderate and significant (ICC > 0.40); 2) is negatively associated with cerebrovascular damage; and 3) is positively associated with the interaction between cardiovascular risk scores and early amyloid-β burden, which may reflect a vascular compensatory response of CBF to early amyloid-β accumulation. These findings encourage future studies to account for multiple interactions with CBF in disease trajectory analyses.
Springer eBooks, 2014
The neurotransmitter dopamine plays a role in many different functions of the human brain, rangin... more The neurotransmitter dopamine plays a role in many different functions of the human brain, ranging from psychomotor planning to cognition. This short review addresses which parts of the dopamine system can be imaged quantitatively in the living human brain using positron-emission tomography (PET) or single-photon emission computed tomography (SPECT).
Springer eBooks, Nov 11, 2021
Neurology
Background and Objectives Recently, the US Food and Drug Administration approved the tau-binding ... more Background and Objectives Recently, the US Food and Drug Administration approved the tau-binding radiotracer [18F]flortaucipir and an accompanying visual read method to support the diagnostic process in cognitively impaired patients assessed for Alzheimer disease (AD). Studies evaluating this visual read method are limited. In this study, we evaluated the performance of the visual read method in participants along the AD continuum and dementia with Lewy bodies (DLB) by determining its reliability, accordance with semiquantitative analyses, and associations with clinically relevant variables. Methods We included participants who underwent tau-PET at Amsterdam University Medical Center. A subset underwent follow-up tau-PET. Two trained nuclear medicine physicians visually assessed all scans. Inter-reader agreement was calculated using Cohen κ. To examine the concordance of visual read tau positivity with semiquantification, we defined standardized uptake value ratio (SUVr) positivity ...
ISMRM Annual Meeting
The current study assesses neuromelanin sensitive MRI (NM-MRI) as a potential biomarker for treat... more The current study assesses neuromelanin sensitive MRI (NM-MRI) as a potential biomarker for treatment resistance (TR) in first episode schizophrenia patients. NM-MRI is a novel MRI sequence, which indirectly measures dopamine synthesis. Research using positron emission tomography (PET) imaging suggest that TR patients show lower dopamine synthesis than responders. We acquired NM-MRI in 61 first episodes schizophrenia patients. Treatment response was determined during 6 months follow-up. TR patients showed significantly lower NM-MRI signal compared to responders. These findings are in line with previous PET studies and demonstrate the potential of NM-MRI as alternative and more accessible biomarker for TR.
Obesity, Aug 1, 2012
Different types of high‐fat (HF) diets are used to study diet‐induced obesity (DIO) in rodents an... more Different types of high‐fat (HF) diets are used to study diet‐induced obesity (DIO) in rodents and this has led to different phenotypes. This study assesses whether different HF diets differentially affect striatal dopamine D2/3 receptor (DRD2/3) availability, as decreased striatal DRD2/3 availability has been implicated in obesity in relation to reward deficiency for food. Thirty rats were randomized to either a free‐choice HF diet (HF‐choice), a premixed HF diet (HF‐no‐choice), or a standard chow diet for 28 days. Striatal DRD2/3 was measured using 123I‐IBZM storage phosphor imaging at day 29. DRD2/3 availability was significantly decreased in the dorsal striatum in the HF‐choice rats compared to chow rats, but not in HF‐no‐choice rats. Additionally, caloric intake of the HF‐choice rats was significantly higher than that of HF‐no‐choice rats and serum leptin and percentage abdominal fat store weight of total body weight were significantly higher in the HF‐choice rats compared to chow rats. These preliminary results suggest that the choice element in HF diets, which is possibly related to the motivational aspects of eating, leads to overconsumption and to a distinct state of obesity. These results are relevant for future studies on DIO when considering choice of diet type.
Therapeutic Advances in Psychopharmacology, 2019
Treatment resistance (TR) in psychosis is a major clinical problem. A biomarker predicting TR aga... more Treatment resistance (TR) in psychosis is a major clinical problem. A biomarker predicting TR against conventional antipsychotic drugs would be relevant, potentially reducing unnecessary delay to adequate treatment with clozapine. Dopa decarboxylase (DDC) activity in the striatum, measured with positron emission tomography, is elevated in responders, but not in treatment-resistant patients. Plasma DDC activity could be a surrogate marker for DDC brain activity, and thus a potential biomarker that could be used in daily clinical practice. Therefore, we determined plasma DDC activity in 40 male patients with recent-onset psychosis, of whom the majority had started treatment, whereby 21 turned out to be treatment responders and 19 treatment resistant during follow up. We observed no significant group differences. Furthermore, symptom severity was not associated with plasma DCC activity. We did observe a trend level difference in the distribution of plasma DDC activity across categories of medication, with subsequent post hoc analysis showing lower DDC activity in risperidone-using patients. This may suggest that risperidone could influence plasma DDC activity. Based on these results, plasma DDC activity does not appear to be a promising biomarker for TR in recent-onset psychosis patients who are already receiving antipsychotic treatment.
Neuroscience applied, 2023
Oxford University Press eBooks, Feb 1, 2016
Neurobiological aspects of obesity: dopamiNe, serotoNiN, aNd imagiNg academiscH proefscHrift ter ... more Neurobiological aspects of obesity: dopamiNe, serotoNiN, aNd imagiNg academiscH proefscHrift ter verkrijging van de graad van doctor aan de universiteit van amsterdam op gezag van de rector magnificus prof. dr. d.c. van den boom ten overstaan van een door het college voor promoties ingestelde commissie, in het openbaar te verdedigen in de agnietenkapel op woensdag 14 november 2012, te 14:00 uur door elisabeth maaike van de giessen geboren te papendrecht promotiecommissie promotores: prof. dr. J. booij prof. dr. W. van den brink co-promotores: prof. dr. f. baas dr. s.e. la fleur overige leden: prof. dr. e. derks prof. dr. b.l.f. van eck-smit prof. dr. a. Jansen prof. dr. t.J. de Vries dr. l. reneman faculteit der geneeskunde Voor Mark geNeral iNtroductioN aNd outliNe of tHesis geNeral iNtroductioN obesity obesity is a condition with an excess proportion of body fat. the most commonly used definition for obesity, as defined by the World Health organization (WHo), is a body mass index (bmi) of > 30 kg/m 2 , whereas a bmi between 25-30 kg/m 2 is defined as overweight, a bmi between 18.5-25 kg/m 2 as normal-weight, and a bmi below 18.5 kg/m 2 as underweight. in addition, the category morbid obesity has been used for people with a bmi > 40 kg/m 2. the growing obesity epidemic is a well-recognized health problem. in the united states, over 30% of the adult population is obese (1). in the Netherlands, this number has doubled from 5.3% in 1981 to 11.4% in 2011 (staline.cbs.nl). the obesity epidemic is not restricted to the Western world (2), but is also increasing in urban areas of some low-and middle-income countries (fig. 1). obesity leads to higher mortality and is a major risk factor for diabetes mellitus, cardiovascular diseases, cancers, musculoskeletal disorders, major depression and also alzheimer's disease (3;4) the cause of obesity is an energy imbalance, i.e. too much energy intake relative to energy expenditure, leading to accumulation of fat mass in the body. the rise of the availability of palatable food, usually high-caloric food rich in sugars and fat, goes hand in hand with the rise in obesity (5;6) and is considered one of the major causes. still, the question remains why some people become obese and some do not in this high-caloric environment. this is a complex problem involving amongst others genetic factors and gene-environment interactions that influence metabolic and psychological mechanisms for regulation of food intake. Elsmarieke van de Giessen Silja McIlwrick dick Veltman Wim van den Brink Jan Booij in preparation.
European Neuropsychopharmacology, Mar 1, 2023
Springer eBooks, 2014
The brain is important in the regulation of eating behavior and satiety signaling. There is also ... more The brain is important in the regulation of eating behavior and satiety signaling. There is also evidence that many neurotransmitters are involved in food intake regulation and eating behavior; consequently dysregulated neurotransmitter systems may be involved in the pathophysiology of obesity. This chapter presents an overview of results of neurotransmitter imaging studies in obese humans and compares the findings to the available knowledge of animal research and to the literature on addiction and eating disorders.
Movement Disorders, Mar 15, 2022
European Neuropsychopharmacology, Apr 1, 2012
The novel triple monoamine inhibitor tesofensine blocks dopamine, serotonin and norepinephrine re... more The novel triple monoamine inhibitor tesofensine blocks dopamine, serotonin and norepinephrine reuptake and is a promising candidate for the treatment of obesity. Obesity is associated with lower striatal dopamine D2 receptor availability, which may be related to disturbed regulation of food intake. This study assesses the effects of chronic tesofensine treatment on food intake and body weight in association with changes in striatal dopamine D2/D3 receptor (D2/3R) availability of dietinduced obese (DIO) rats. Four groups of 15 DIO rats were randomized to one of the following treatments for 28 days: 1. tesofensine (2.0 mg/kg), 2. vehicle, 3. vehicle+ restricted diet isocaloric to caloric intake of group 1, and 4. tesofensine (2.0 mg/kg) +a treatment-free period of 28 days. Caloric intake and weight gain decreased significantly more in the tesofensine-treated rats compared to vehicle-treated rats, which confirms previous findings. After treatment discontinuation, caloric intake and body weight gain gradually increased again. Tesofensine-treated rats showed significantly lower D2/3R availability in nucleus accumbens and dorsal striatum than both vehicle-treated rats and vehicle-treated rats on restricted isocaloric diet. No correlations were observed between food intake or body weight and D2/3R availability. Thus, chronic tesofensine treatment leads to decreased food intake and weight gain. However, this appears not to be directly related to the decreased striatal D2/3R availability, which is mainly a pharmacological effect.